Skip to main content

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging System(TM) on Schedule for Completion in 2022

  • Imagin Medical’s contract manufacturer, Lighthouse Imaging, has developed a program focused on refining the i/Blue System’s design for manufacturing
  • Lighthouse’s manufacturing process will ensure that regulatory standards are followed while maintaining optimal performance and staying within targeted costs
  • Imagin is currently focusing on using the i/Blue system for bladder cancer visualization with plans to extend the use of the technology to other procedures in the future

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is on track to complete its patented i/Blue Imaging System(TM) in 2022. The innovative technology leverages proprietary light sensors and optics to improve the accuracy and efficiency of bladder cancer visualization and removal, potentially reducing recurrence rates.

The manufacturing progress reported to-date can be largely attributed to the company selecting Lighthouse Imaging, an FDA registered and ISO 13485:2016 certified manufacturer, as its contract manufacturer. According to a press release, Lighthouse’s development program is focused on…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.